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ABSTRACT
Introduction Vision impairment and eye disease are major 
global health concerns and have been associated with 
increased morbidity and mortality, and lower quality of life. 
Quality of life, whether generic, vision- specific or disease- 
specific, is an important measure of the impact of eye health 
on people’s daily activities, well- being and visual function, 
and is increasingly used to evaluate the impact of ophthalmic 
interventions and new devices. While many studies and 
reviews have examined the relationship between vision or eye 
health and quality of life across different contexts, there has 
yet to be a synthesis of the impact of vision impairment, eye 
disease and ophthalmic interventions on quality of life globally 
and across the lifespan.
Methods and analysis An umbrella review of systematic 
reviews will be conducted to address these two questions: (1) 
What is the association of vision impairment and eye disease 
with quality of life? (2) What is the impact of ophthalmic 
interventions on quality of life? A search of related literature 
will be performed on the 11 February 2020 in Medline Ovid,  
Embase. com, Cochrane Database of Systematic Reviews, 
Proquest Dissertations and Theses Global, and the grey 
literature, and repeated at the synthesis stage. Title/abstract 
and full- text screening, methodological quality assessment 
and data extraction will be conducted by reviewers working 
independently and in duplicate. Assessment of methodological 
quality and data extraction will be performed using Joanna 
Briggs Institute standard forms. Findings from the systematic 
reviews and their methodological quality will be summarised 
qualitatively in the text and using tables.
Ethics and dissemination No ethical approval is 
required. Results of this umbrella review will be published 
in a peer- reviewed journal and summarised in the Lancet 
Global Health Commission on Global Eye Health.
Trial registration number This protocol was registered 
in the Open Science Framework Registries (https:// osf. io/ 
qhv9g/).
INTRODUCTION
Vision impairment is a major cause of disability 
worldwide.1 In 2015, an estimated 36 million 
people were blind, 217 million had moderate 
or severe vision impairment and over a billion 
people experienced near- vision impairment 
(presbyopia).2 Cataract and uncorrected refrac-
tive error are correctable conditions which 
accounted for 78% of global visual impairment 
that year.3 Despite reductions in age- specific 
prevalence, the number of people with vision 
impairment and blindness is projected to 
increase due to population growth and ageing.2 
Vision impairment is associated with nega-
tive health outcomes, such as having multiple 
chronic conditions,4 5 and increased mortality,6 
and also induces substantial socioeconomic 
consequences for individuals,7 and an associ-
ated lower quality of life.
Objective clinical measures, like visual acuity, 
intraocular pressure or fundus imaging, are 
widely used in the clinical and research settings 
to assess eye health, but often fail to capture the 
impact of vision impairment or eye disease on 
individuals’ daily activities or social well- being.8 
Quality- of- life instruments, on the other hand, 
measure patient- reported outcomes, such as 
perceived health, physical, mental, emotional 
or social well- being, and even vision- specific 
function. These measures are important as 
vision impairment can have a large impact 
on quality of life, possibly to an even greater 
degree than major conditions such as stroke, 
heart disease or diabetes.9 Both severe condi-
tions that lead to marked reduction in vision 
like age- related macular degeneration,10 and 
Strengths and limitations of this study
 ► The umbrella review approach allows for a compre-
hensive review of a very broad topic by summarising 
the evidence from multiple research syntheses into 
one systematic review of reviews.
 ► Study screening, critical appraisal and data collec-
tion will be conducted in duplicate.
 ► Standardised forms developed specifically for the 
conduct of umbrella reviews will be used for critical 
appraisal and data collection.
 ► Studies related to rare topics or special settings 
might not be included in systematic reviews, and 
thus would not be represented in this umbrella re-
view, a main limitation of our work.
 ► Only systematic reviews published in English will be 
included.
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highly symptomatic conditions which may not be associated 
with impaired vision, like dry eye syndrome,11 have been 
associated with decreased health- related quality of life.
The use of quality- of- life instruments has gained popu-
larity in ophthalmic studies, including clinical trials, over 
the past decade.12 While there is a wide range of quality- 
of- life instruments available, vision- related quality- of- life 
instruments are frequently used in ophthalmic studies, 
as these questionnaires are more sensitive to the impact 
of subtle vision changes on daily function compared with 
more general health- related or generic quality- of- life 
tools.13 Reduced visual acuity14 and visual field loss15 are 
both associated with worsening in vision- related quality 
of life; glaucoma16–19 and cataract16 19 are associated with 
worse vision- related function, independent of visual 
acuity. In ophthalmic clinical trials, health- related, vision- 
related and even disease- specific scales have been used 
as secondary outcome measures, and more recently, as 
primary outcomes as well.20 21 Patient- reported outcomes 
are also increasingly being incorporated in the evalua-
tion of new ophthalmic devices, and the Food and Drug 
Administration even provides guidance on using them to 
support labelling claims too.22 23
There has yet to be a global assessment of the impact 
of eye health, including vision impairment, eye disease 
and ophthalmic interventions on quality of life across 
the lifespan, despite the growing number of ophthalmic 
studies assessing quality of life, and increased value placed 
on patient- reported outcomes. Prior studies on vision and 
quality of life have usually focused on specific countries (eg, 
USA,24 Finland,25 South Korea,26 Nigeria27), populations 
(eg, Malay population in Singapore,28 Latino population29 
and indigenous peoples of the Americas30 in the USA) or 
settings (eg, community,31 outpatient clinics32). Even reviews 
summarising the evidence about the impact of vision on 
quality of life have usually focused on specific age groups 
(eg, children,33 34 older adults35), eye conditions (eg, glau-
coma,36 diabetic retinopathy,37 dry eye38) or interventions 
(eg, low vision rehabilitation for children,34 anti- vascular 
endothelial growth factor therapy for age- related macular 
degeneration39).
This umbrella review (or systematic review of systematic 
reviews) will examine the impact of vision impairment, 
eye disease and ophthalmic interventions on quality of 
life globally and across the lifespan. An umbrella review 
approach allows us to maintain a broad scope while 
relying on the highest quality of evidence, given the large 
number of primary studies9–11 14–19 24–32 and reviews on 
this topic.34–41 A search of three systematic review regis-
tries (the International Prospective Register of Systematic 
Review [PROSPERO], Joanna Briggs Institute Systematic 
Review Register, and Open Science Framework Regis-
tries) has shown that there is currently no systematic or 
umbrella review underway for this topic.
Objectives and questions
This umbrella review of systematic reviews aims to identify 
and synthesise currently available knowledge about the 
association of vision and eye disease with quality of life on 
a global level. Two questions will be addressed:
1. What is the association between vision impairment or 
eye disease and quality of life?
2. What is the impact of ophthalmic interventions on 
quality of life?
METHODS AND ANALYSIS
This protocol was registered in the Open Science Frame-
work Registries (https:// osf. io/ qhv9g/). It was designed 
by following the Joanna Briggs Institute guidelines for 
the conduct and preparation of umbrella reviews,42 and 
the Preferred Reporting Items for Systematic review and 
Meta- Analysis Protocols guidelines for the reporting of 
systematic review protocols (online supplementary file 
1).43 The anticipated start date of this study is 11 February 
2020. Any changes to the methodological approach will 
be dated and described in detail in the final umbrella 
review report.
Inclusion criteria
Systematic reviews and meta- analyses that evaluate the 
impact of vision impairment, eye disease or ophthalmic 
interventions on quality of life will be included in this 
umbrella review.
Types of participants
Systematic reviews of studies with participants who have 
vision impairment or an eye disease will be included. 
Vision impairment can be self- reported or assessed objec-
tively, using any measure of visual function, including, but 
not limited to, visual acuity (corrected or uncorrected, 
distance or near), contrast sensitivity or visual fields. Eye 
disease diagnosis can be based on self- report, medical 
chart or claims data or an objective assessment of symp-
toms, clinical signs or imaging findings. Eye diseases that 
will be explored include, but are not limited to, the WHO 
priority eye diseases, which are the most common causes 
of vision impairment worldwide: cataract, onchocerciasis, 
trachoma, refractive errors, age- related macular degener-
ation, diabetic retinopathy, glaucoma, corneal opacities, 
childhood blindness and genetic eye diseases.44
Systematic reviews with sample populations from any 
age group (children, working- age adults or older adults), 
country (low, middle or high income) or setting (commu-
nity, hospital, clinic, institution) will be included.
Interventions
Systematic reviews that examine interventions will also be 
included and will help answer the second question specif-
ically, the impact of ophthalmic interventions on quality 
of life. The comparison group can be the same group 
preintervention, another group that receives another 
intervention, or another group receiving no intervention. 
Any ophthalmic intervention identified will be included, 
as long as its main aim is to correct or improve vision, 
slow down the progression of vision loss, improve func-
tional ability among those with vision loss (eg, low vision 
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rehabilitation, use of assistive devices) or relieve eye pain 
or discomfort.
Outcomes
Studies that measure any aspect of quality of life (generic 
or health- related, vision- related or disease- specific) will 
be included. Studies can report on one or all domains 
used to measure quality of life. Systematic reviews of both 
quantitative and qualitative studies are eligible for inclu-
sion. Examples of quality- of- life instruments are the WHO 
Quality of Life Assessment Instrument (health- related 
quality of life), the National Eye Institute Vision Func-
tion Questionnaire (vision- related quality of life) and the 
Catquest- 9SF questionnaire (cataract- specific quality of 
life).
Types of studies
Only systematic reviews (with or without and meta- 
analyses) are eligible for inclusion. A systematic review 
will be defined as a review that includes every one of 
these items: a research question, a search strategy with 
the sources searched, inclusion and exclusion criteria, 
screening methods, a discussion about the quality of 
included studies and risk of bias and information about 
data analysis and synthesis.45 Systematic reviews of obser-
vational and interventional studies will be included, but 
those that incorporate case series or expert opinion as 
their source of evidence will be excluded. All other types 
of reviews including narrative reviews and scoping reviews 
will be excluded.
Search strategy
An academic librarian developed a comprehensive search 
strategy based on similar ones used by Cochrane Eyes and 
Vision Group. Search strategies were developed using 
a combination of controlled vocabulary and keywords 
to represent vision terms, eye diseases, including all the 
WHO priority eye disease listed above, and ophthalmic 
interventions, as well as search terms for quality of life, 
including some commonly used scales, and terms to iden-
tify systematic reviews (see online supplementary file 2 for 
a detailed search strategy).
The following databases will be searched on 11 February 
2020: Medline Ovid (1946 to present),  Embase. com (1947 
to present), Cochrane Database of Systematic Reviews 
(1995 to present), Proquest Dissertations and Theses 
Global (1861 to present). A search for grey literature 
will include sources such as reports from governments 
and non- governmental organisations, and databases 
including the Open Grey and the Agency for Healthcare 
Research and Quality. The search will be limited to arti-
cles published in English with no restrictions on the year 
of publication. We will search the references of included 
studies for additional systematic reviews.
The search will be run again in the synthesis stage to 
identify any relevant reviews published since the initial 
search.
Study selection
Citations retrieved from the searches will be imported to 
Endnote, where any duplicates will be removed. Then, 
references will be imported to Covidence, a web- based soft-
ware platform that streamlines the production of system-
atic reviews. Four reviewers will work in pairs to screen 
the studies independently and in duplicate. Conflicts will 
be discussed in the presence of a third reviewer from the 
second pair; if no consensus is reached, the senior author 
will be consulted.
Review selection will take place at the level of title/
abstract and full text. Reviews judged to be of insufficient 
quality for inclusion will also be excluded at the method-
ological assessment stage. Articles will first be screened at 
the level of the titles and abstracts. At this stage, all system-
atic reviews and meta- analyses, published in English, and 
that address a vision- related topic (vision impairment, eye 
disease or ophthalmic intervention) and quality of life 
will be included. Articles that are identified as systematic 
reviews in the title or abstract, using the terms ‘systematic 
review’ or ‘meta- analysis’, will be included. Reviews that 
are not explicitly identified as such will be moved to full- 
text review if the methods suggest they may be systematic 
reviews based on the definition used above. Reviews that 
are clearly not related to quality of life will be excluded 
at this stage, but reviews of interventional studies that 
do not specifically address quality of life in their title or 
abstract will go to full- text review, as quality of life may be 
a secondary outcome that is only mentioned in the text.
In the next step, the included reviews will undergo 
full- text screening and will be included if they meet 
the criteria listed above for a systematic review, if none 
of their primary studies are case series/case reports or 
expert opinion, and if they specifically assess the impact 
of the vision- related topic on quality of life. The final 
study selection will be made after assessment of method-
ological quality. Reasons for exclusion will be logged.
Assessment of methodological quality
Systematic reviews that are deemed eligible for inclusion 
will be assessed for their methodological quality using the 
Joanna Briggs Institute Critical Appraisal Checklist for 
Systematic Reviews and Research Syntheses.46 The four 
reviewers will work again in pairs to do the assessment 
independently and in duplicate. Joanna Briggs Institute 
SUMARI, a web- based review software that has partnered 
with Covidence, will be used to facilitate the critical 
appraisal step.
The Joanna Briggs Institute Critical Appraisal Check-
list contains 11 items related to systematic review meth-
odology, each graded as ‘Yes’, ‘No’, ‘Unclear’ or ‘Not 
Applicable’. It can be used to appraise both quantita-
tive and qualitative systematic reviews. The form will be 
piloted by the four reviewers by testing it on two studies 
before starting independent appraisals; these reviewers 
will compare their results and discuss what constitutes an 
acceptable level of information to decide if a review meets 
or does not meet the criteria, and when is it ‘Unclear’. 
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Systematic reviews for which at least one of the items 
‘clear review question’, ‘appropriate inclusion criteria’, 
‘appropriate search strategy’, or ‘appropriate criteria for 
critical appraisal’ are graded as ‘Unclear’ or ‘No’ will be 
considered to be of insufficient quality for inclusion, and 
as such would be excluded at this stage.
Results of the quality appraisal for each review will 
be presented in a table, and the overall methodological 
quality of the included reviews will be summarised in the 
text.
Data collection
Data will be extracted from the final list of articles included 
using the Joanna Briggs Institute Data Extraction Form 
for Review for Systematic Reviews and Research Syntheses 
(see online supplementary file 3 for a blank copy of the 
sample data extraction sheet).42 Again, the four reviewers 
will work in pairs to extract the data independently and 
in duplicate, using the Joanna Briggs Institute SUMARI 
software.
In brief, the standardised form will be used to extract 
information about citation details (eg, author, year), 
systematic review methodology (eg, objectives, partici-
pants, setting/context, search strategy, appraisal instru-
ment used), characteristics of the included studies (eg, 
date range, number and types of studies, country of origin, 
rating of their quality, outcomes reported) and findings 
of the systematic review (eg, method of synthesis/anal-
ysis employed, results/findings). Additionally, informa-
tion about the review’s funder or sponsor and their role, 
when applicable, and the reviewers’ overall assessment of 
the quality of the evidence, such as Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE), will be collected. The GRADE quality assess-
ment is based on the primary studies’ quality and design, 
and the consistency and directness of the findings.47
In the comments section, the following information will 
be indicated: (1) if the review is about vision impairment/
eye health or an ophthalmic intervention, (2) the func-
tional vision measure used or eye disease or intervention, 
(3) if the population belongs to a specific age group, 
country income group or setting. This will help classify 
the reviews for the synthesis.
Before the reviewers start collecting data independently, 
the form will be piloted. All four reviewers will extract 
data from two articles, compare their answers and discuss 
them to ensure that they all interpret the questions in the 
same way.
Data summary
A qualitative synthesis of the findings will be presented in 
the text and using tables describing study characteristics 
and the overall umbrella review results (summary of find-
ings). When presenting study characteristics, studies will 
first be divided according to the question they address: 
the impact of vision impairment or eye disease on quality 
of life, or the impact of ophthalmic interventions on 
quality of life. Each question will have a table for the 
quantitative systematic reviews, and another one for the 
qualitative systematic reviews, as the study characteristic 
information reported/presented for each is different. 
Within each table, results will be stratified according to 
the outcome measured (health- related, vision- related or 
condition- specific quality of life), and functional vision 
measured, eye disease or intervention (figure 1).
Study characteristics tables for the quantitative system-
atic reviews will include the following information: the 
number of studies in the systematic review, the number 
of participants from the included studies, estimates 
computed and the heterogeneity of the results. For 
qualitative systematic reviews, the final synthesised find-
ings will be presented along with information about the 
study context. Overlaps of original research studies in the 
included systematic reviews will be presented.
Summary of findings tables will present an overall 
summary for each question, exposure, outcome and, 
Figure 1 Organisation of findings. Reviews will be divided according to the question they address (question 1 being vision 
impairment/eye disease, and question 2, ophthalmic interventions). For each question, reviews will be categorised as 
quantitative or qualitative, and within each category, they will be further grouped based on their quality- of- life measure and 
exposure (specific functional vision measure or eye disease for question 1, and intervention for question 2). Summary of findings 
tables will be further stratified by study population depending on the results available; potential subgroups include age category 
(children, working- age adults or older adults), country (low, middle or high income) or setting (community, hospital, clinic, 
institution).
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when applicable, subgroup (age, country income group, 
setting; figure 1), along with an assessment of the strength 
of the evidence for each finding, such as GRADE, when 
included in the review.
Study limitations
The study methodology has some limitations that may 
impact the final results of the review. Using the umbrella 
review approach limits the results to those found in arti-
cles that have been included in systematic reviews. While 
this means that studies about rare diseases or topics that 
have not yet been addressed by systematic reviews will 
not be included, it is this approach that will allow us to 
perform a global assessment of a broad topic in a system-
atic manner. Moreover, using strict criteria to define a 
systematic review, and limiting inclusion to those that 
meet certain quality requirements may further decrease 
the number of studies included, but it will allow us to 
focus on the available high- quality evidence. In regard 
to the first question, vision impairment and eye diseases 
may be defined and diagnosed differently in each review, 
thus making it harder to combine the evidence. Likewise, 
a large number of interventions may be identified for 
the second question, and the type of comparison groups 
might differ between reviews (intervention compared with 
no intervention or intervention compared with another 
intervention), making the synthesis of the evidence chal-
lenging. However, using the methods detailed above to 
present the results and summarise the findings will allow 
us to organise the findings in a systematic manner and 
present enough context for the reader to interpret the 
results. Finally, as with any umbrella review, there may be 
overlap in the primary studies included in each systematic 
review; however, we will highlight any overlap of studies 
in the tables.
Patient and public involvement
There is no patient or public involvement in this study.
ETHICS AND DISSEMINATION
Only published studies will be examined for this system-
atic review; therefore, no ethical approval is required. 
If any changes to the protocol are made, they will be 
described in the final umbrella review report.
Results from this study will be published in a peer- 
reviewed journal and summarised in The Lancet Global 
Health Commission on Global Eye Health.
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